<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652050</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20080119</org_study_id>
    <nct_id>NCT04652050</nct_id>
  </id_info>
  <brief_title>Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation</brief_title>
  <acronym>Tolsura</acronym>
  <official_title>Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Nguyen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, observational study of Tolsura PK sampling in lung transplant&#xD;
      recipients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are receiving Tolsura as part of their clinical care will be asked to enroll and&#xD;
      EMR data and excess biological samples will be collected&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>PK Sampling-measure amount of drug in system</measure>
    <time_frame>one day PK sampling</time_frame>
    <description>blood samples around a dosing of Tolsura to determine maximum plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rates of infection post treatment with Tolsura</measure>
    <time_frame>6 months</time_frame>
    <description>follow lung transplant recipients till end of Tolsura treatment and determine rates of infection for as well as type of infections</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Transplant Infection</condition>
  <arm_group>
    <arm_group_label>lung transplants</arm_group_label>
    <description>Lung transplants on Tolsura for infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMR Collection on use and outcomes of Tolsura</intervention_name>
    <description>Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.</description>
    <arm_group_label>lung transplants</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      excess biological samples collected as part of the patient's clinical care will be obtained&#xD;
      if available for further testing/analysis for amounts of Tolsura&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        lung transplants on Tolsura that meet entry criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  hospitalized at UPMC&#xD;
&#xD;
          -  placed on Tolsura prophylactically by clinical team&#xD;
&#xD;
          -  patients who have had or will have a lung transplant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  redo lung transplant&#xD;
&#xD;
          -  recipient with dual liver-lung transplant&#xD;
&#xD;
          -  patients with previous history of SOT&#xD;
&#xD;
          -  including other organ transplantation&#xD;
&#xD;
          -  patients with known pre-transplant colonization with moulds resistant to azoles&#xD;
&#xD;
          -  patients with intra-transplant positive cultures for moulds in either transplant&#xD;
             recipient or his/her donor&#xD;
&#xD;
          -  patients with a history of hypersensitivity reaction to an azole agent&#xD;
&#xD;
          -  patients who are kept NPO (nothing by mouth, including meds)&#xD;
&#xD;
          -  recipients or donor with HepC PCR positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC and PITT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Nguyen, MD</last_name>
    <phone>412-383-5193</phone>
    <email>mhn5@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Lynn Pakstis, RN, BSN</last_name>
    <phone>412-648-6553</phone>
    <email>dlp5@pitt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Nguyen, MD</last_name>
      <phone>412-383-5193</phone>
      <email>mhn5@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diana Lynn Pakstis, RN, BSN</last_name>
      <phone>412-648-6553</phone>
      <email>dlp5@pitt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hong Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Hong Nguyen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lung transplant</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If data is shared all data provided de identified using alpha/numeric codes and MTA and/or DUA's will be in put in place prior to sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

